These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 29643855)
1. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT. Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A Front Immunol; 2018; 9():631. PubMed ID: 29643855 [TBL] [Abstract][Full Text] [Related]
2. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling. Jin B; Ding K; Pan J Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773 [TBL] [Abstract][Full Text] [Related]
3. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells. Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810 [TBL] [Abstract][Full Text] [Related]
4. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase. Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996 [TBL] [Abstract][Full Text] [Related]
5. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801 [TBL] [Abstract][Full Text] [Related]
6. Usage of sphingosine kinase isoforms in mast cells is species and/or cell type determined. Dillahunt SE; Sargent JL; Suzuki R; Proia RL; Gilfillan A; Rivera J; Olivera A J Immunol; 2013 Mar; 190(5):2058-67. PubMed ID: 23359503 [TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis. Bandara G; Falduto GH; Luker A; Bai Y; Pfeiffer A; Lack J; Metcalfe DD; Olivera A Front Immunol; 2023; 14():1078958. PubMed ID: 37025992 [TBL] [Abstract][Full Text] [Related]
8. KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells. Chan EC; Bai Y; Bandara G; Simakova O; Brittain E; Scott L; Dyer KD; Klion AD; Maric I; Gilfillan AM; Metcalfe DD; Wilson TM Exp Hematol; 2013 Oct; 41(10):870-881.e2. PubMed ID: 23743299 [TBL] [Abstract][Full Text] [Related]
9. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739 [TBL] [Abstract][Full Text] [Related]
10. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Orfao A; Garcia-Montero AC; Sanchez L; Escribano L; Br J Haematol; 2007 Jul; 138(1):12-30. PubMed ID: 17555444 [TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis. Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453 [TBL] [Abstract][Full Text] [Related]
15. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation. Jin Y; Ding K; Wang D; Shen M; Pan J Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577 [TBL] [Abstract][Full Text] [Related]
16. Mastocytosis: from a Molecular Point of View. Komi DEA; Rambasek T; Wöhrl S Clin Rev Allergy Immunol; 2018 Jun; 54(3):397-411. PubMed ID: 28725969 [TBL] [Abstract][Full Text] [Related]
17. Distinct signalling pathways for mutated KIT(V560G) and KIT(D816V) in mastocytosis. Chan IJ; Kasprowicz S; Tharp MD Clin Exp Dermatol; 2013 Jul; 38(5):538-44. PubMed ID: 23777495 [TBL] [Abstract][Full Text] [Related]
18. Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT. Bibi S; Arock M Immunol Allergy Clin North Am; 2018 Aug; 38(3):527-543. PubMed ID: 30007468 [TBL] [Abstract][Full Text] [Related]
20. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit. Pedersen M; Rönnstrand L; Sun J Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]